Concepedia

Parthasarathy Rangarajan

PR

Statistics

Publications

5

Citations

174

H-Index

5

Active since

2008

Affiliations

The University of Kansas Cancer Center(Current)

University of Kansas Medical Center

Parthasarathy Rangarajan is an author at The University of Kansas Cancer Center specializing in pharmacology, oncology, and medicine.

ORCID

Publications per year

2008–2021

5

Publications

5

Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells

Parthasarathy Rangarajan, Dharmalingam Subramaniam, Santanu Paul et al. · Oncotarget · 2015 · 57 citations · Full text

, , +17

Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells

Gaurav Kaushik, Satish Ramalingam, Dharmalingam Subramaniam et al. · The American Journal of Surgery · 2012 · 47 citations

, , +12

Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth

Sivapriya Ponnurangam, David Standing, Parthasarathy Rangarajan et al. · Molecular Cancer Therapeutics · 2013 · 44 citations

, , +16

Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex

Scott J. Weir, Prasad Dandawate, David Standing et al. · Cell Death and Disease · 2021 · 14 citations · Full text

, , +15

Antitumor and antioxidant potential of Tragia Plukenetii R.Smith on Ehrlich ascites carcinoma in mice

Meenakshi Sundaram, Sudarsanam Dorairaj, Parthasarathy Rangarajan et al. · AFRICAN JOURNAL OF BIOTECHNOLOGY · 2008 · 12 citations · Full text

, , +13

1–5 of 5